SourceBio International PLC Which? endorsement for day two travel PCR test
October 22 2021 - 2:00AM
RNS Non-Regulatory
TIDMSBI
SourceBio International PLC
22 October 2021
22 October 2021
SourceBio International plc
("SourceBio", the "Company" or "the Group")
Which? endorsement for day two travel PCR test
SourceBio International plc (AIM: SBI), a leading international
provider of integrated state-of-the-art laboratory services and
products , notes an online article published by Which? titled 'The
best cheap day two Covid tests for travel' that recommends
SourceBio as the best provider of day two travel COVID-19 PCR
testing among a cohort of 50 companies supplying home testing kits,
found on www.Gov.uk.
Which? is a non-for-profit organisation which provides impartial
expert advice and recommendations to help consumers make better
decisions. During the review, Which? applied various criteria to
narrow the list of 50 companies down to 7 to investigate with a
mystery shopper, a common practice used by retailers, market
research and consumer watchdogs to measure the quality of customer
service . Which? then shopped at each supplier 13 times to check
how often the test kits and results arrived on time.
The mystery shop concluded that SourceBio's travel COVID-19 PCR
test was the most reliable of all providers, with test kits and
results arriving on time on 12 out of 13 occasions. The endorsement
from Which? is a significant achievement given the complete
impartiality of the selection process and underlines the excellent
customer service and affordability of the day two PCR testing
service offering by the Group.
Jay LeCoque, Executive Chairman, commented : "We are delighted
to be named by Which? as the best provider of affordable day two
consumer travel PCR testing. Which? is a completely impartial
organisation and their review process involved a comprehensive
mystery shop process, highlighting SourceBio's PCR testing service
as the most reliable out of 50 businesses assessed. Outstanding
customer service has always been central to SourceBio, and we will
continue to maintain this standard as our customers trust us with
their day two travel PCR testing."
For further information please contact:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial
Officer
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups, NHS
and the DHSC. Utilising multiple technologies, including lateral
flow testing solutions, SourceBio offers screening, gold standard
RT-PCR and whole genome sequencing COVID-19 testing solutions and
operates under ISO 15189 accreditation required by the DHSC.
SourceBio also provides employee testing solutions to industry, and
direct to consumer home test kits (including "Fit to Fly", "Test to
Release" and "2 & 8 Day International Travel" approved
tests).
-- Healthcare Diagnostics - histopathology cancer screening and
clinical diagnostic services for the NHS and private healthcare
across the UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here:
www.sourcebioscience.com .
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFVEIDLLFIL
(END) Dow Jones Newswires
October 22, 2021 02:00 ET (06:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024